![](https://www.optimumcomms.com/wp-content/uploads/2023/06/Calliditas_Logo_300x180px-80x80-1-260x180.png)
![](https://www.optimumcomms.com/wp-content/uploads/2023/06/Calliditas_Logo_300x180px-80x80-1-260x180.png)
![](https://www.optimumcomms.com/wp-content/uploads/2023/06/Calliditas_Logo_300x180px-80x80-1-260x180.png)
Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm:…
![](https://www.optimumcomms.com/wp-content/uploads/2023/02/Ariceum_Logo_300x180px-2-260x180.png)
Ariceum Therapeutics Commences Phase 1 Clinical Trial in Patients with Recurrent Glioblastoma
Novel iodine radiolabelled PARP inhibitor (rPARPi) entering…
![](https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4-260x180.png)
Novo Holdings leads $105 million financing of Magenta Medical to support FDA approval for world’s smallest heart pump
Funds will be used to advance Magenta’s US clinical programs…
![](https://www.optimumcomms.com/wp-content/uploads/2024/04/Xeltis_Logo_300x180px-80x80Web_Logos-260x180.png)
Xeltis appoints Shawn Gage as Vice President of US Clinical Affairs
Brings extensive experience in design, development, and implementation…
![](https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4-260x180.png)
Novo Holdings Portfolio Company Invetx to be Acquired by Dechra Pharmaceuticals
Transaction values animal health therapeutics pioneer at…
![](https://www.optimumcomms.com/wp-content/uploads/2023/08/4SC_Logo_300x180px-80x80Web_Logos-1-260x180.png)
4SC receives Orphan Drug Status (ODS) for resminostat (Kinselby) in cutaneous T-cell lymphoma in Switzerland
Swissmedic has granted Orphan Drug Status for resminostat…
![](https://www.optimumcomms.com/wp-content/uploads/2024/01/Vivet_Logo_300x180px-80x80-1-260x185.png)
Dr Gloria Gonzalez-Aseguinolaza, Chief Scientific Officer of Vivet Therapeutics Receives the Rosalind Franklin Society Special Award in Science
Recognition of her pioneering gene therapy research
Coordinated…
![](https://www.optimumcomms.com/wp-content/uploads/2023/02/ASCEneuron_Logo_300px-2-260x180.png)
Asceneuron Secures $100 Million Series C Financing to Advance Groundbreaking Therapeutics in Neurodegenerative Diseases
Financing led by Novo Holdings, including new investment…
![](https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4-260x180.png)
Novo Holdings leads $100 million Series C financing of Asceneuron to advance groundbreaking therapy for Alzheimer’s disease
Funds will be used to progress lead asset ASN51, an oral…
![](https://www.optimumcomms.com/wp-content/uploads/2024/03/Heidelberg_Logo_300x180px-80x80Web_Logos-1-260x180.png)
Heidelberg Pharma Reports on First Half-Year 2024 and the Course of Business
First preliminary efficacy data from the clinical trial with…
![](https://www.optimumcomms.com/wp-content/uploads/2024/06/iOnctura_Logo_300x180px-80x80Web_Logos-260x180.png)
iOnctura announces expansion of roginolisib clinical trial program to NSCLC
• Phase II study in non-small-cell-lung-cancer (NSCLC) to be…
![](https://www.optimumcomms.com/wp-content/uploads/2023/02/CurveTx_Logo_300x180px-80x80-Recovered-260x180.png)
Curve Therapeutics strengthens Leadership Team with appointment of experienced biotech executive Simon Jones
Accomplished CFO and COO with proven track record in the…
![](https://www.optimumcomms.com/wp-content/uploads/2023/10/Oxolife_Logo_300x180px-80x80Web_Logos-260x180.png)
A pill for infertility: Oxolife’s non-hormonal oral drug raises embryo implantation rate, pregnancy rates and live birth rate in women undergoing IVF and ICSI, data being presented at ESHRE shows
A pill for infertility: Oxolife’s non-hormonal oral drug raises…
![](https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4-260x180.png)
Novo Holdings co-leads £90 million ($114 million) Series A financing for Myricx Bio to advance a novel payload class for antibody-drug conjugates
Funds will be used to build out Myricx Bio’s proprietary…
![](https://www.optimumcomms.com/wp-content/uploads/2024/03/Mission_Therapeutics_Logo_300x180px-80x80Web_Logos-1-260x180.png)
Mission Therapeutics awarded $5.2m from The Michael J. Fox Foundation and Parkinson’s UK to advance potential disease-modifying treatment MTX325
Investment will support investigation of Mission’s small…
![](https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4-260x180.png)
Novo Holdings invests in MATR Foods’ expansion within plant-based fungi food
COPENHAGEN, DENMARK – Today, Novo Holdings announced an initial…
![](https://www.optimumcomms.com/wp-content/uploads/2023/02/Bionical_Logo_300px-1-260x180.png)
Tom Tacon appointed Business Unit Director of Bionical Virtual Engagement
Willington, UK, June 27, 2024 – Bionical Solutions, a leading…
![](https://www.optimumcomms.com/wp-content/uploads/2024/05/Template_Logo_300x180px-80x80Web_Logos-1-260x180.jpg)
Resolution Therapeutics Receives MHRA Approval to Commence Phase I/II EMERALD Study for Lead Candidate RTX001
EMERALD Study will investigate safety and efficacy of engineered…
![](https://www.optimumcomms.com/wp-content/uploads/2024/06/Template_Logo_300x180px-80x80Web_Logos-260x180.jpg)
Fostrox + Lenvima® holds promise of greatly improved outcomes for advanced liver cancer patients, reveals new data from Medivir at ESMO GI
New results from Medivir’s Phase 1b / 2a open label trial…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York